Article Text


THU0183 Significantly improved upper gastrointestinal (ugi) tolerability with celecoxib, a cox-2 specific inhibitor, compared with conventional nsaids. the success i trial
  1. JL Goldstein1,
  2. N Agrawal2,
  3. G Eisen3,
  4. W Stenson4,
  5. AE Bello5,
  6. JG Fort5,
  7. SP Boots5
  1. 1Department of Medicine, University of Illinois at Chicago, Chicago
  2. 2Department of Medicine, Duke University Medical Center, Durham
  3. 3Department of Medicine, Vanderbilt University Medical Center, Nashville
  4. 4Department of Medicine, Washington University Medical School, St Louis
  5. 5Research and Development, Pharmacia Corporation, Skokie, USA


Background The Celecoxib Long-term Arthritis Safety Study (CLASS), a prospective outcomes study conducted in North America, demonstrated a significant reduction in UGI ulcer complications and improved tolerability.

Objectives To extend our understanding of the UGI safety advantages of celecoxib over conventional nonsteroidal anti-inflammatory drugs (NSAIDs), in day-to-day practice, a naturalistic study was conducted worldwide.

Methods SUCCESS I, a large, 12-week, multinational, double-blind, randomised trial in 13,274 osteoarthritis patients, was conducted in 39 countries. There were 6547 patients from Europe/Africa, 2756 from North America, 2889 from Latin America, and 1082 from Asia/Pacific. Celecoxib 200 mg/d (n = 4421) and 400 mg/d (n = 4429) was compared with naproxen 1000 mg/d (n = 914) and diclofenac 100 mg/d (n = 3510) with regard to GI tolerability.

Results The frequency of all reported GI adverse events (AEs), the three most frequently reported UGI AEs, and withdrawals due to GI AEs are shown in the Table 1.

Abstract THU0183 Table 1

Conclusion UGI symptoms, more commonly associated with NSAID use, were consistently and significantly lower with celecoxib. The percent reduction ranged from 18.6% to 29.4%. These data confirm the superior GI tolerability of celecoxib vs conventional NSAIDs and establish that this difference is clinically meaningful in terms of discontinuation of therapy for such symptoms. Sponsored by Pharmacia Corporation and Pfizer, Inc.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.